Lunit

Lunit develops deep‑learning‑powered medical imaging AI solutions that assist clinicians in detecting cancer and radiologic abnormalities to improve diagnosis speed and quality.

Pricing Model: Paid

Category: Health and Wellness Ai Tools

https://www.lunit.io/en

Release Date: 27/11/2017

• AI‑powered analysis of chest X‑rays to detect lung nodules, masses and abnormalities
• AI‑assisted mammography and digital breast tomosynthesis for breast‑cancer screening
• Visualization of attention maps and lesion highlighting to aid clinician review
• Cloud and on‑premise deployment options tailored for clinical environments
• Regulatory clearances and clinical evidence from peer‑reviewed studies
• Integration with PACS, RIS and radiology workflows for seamless adoption
• Quantitative imaging biomarkers to support precision‑oncology decision making
• Automated triage and prioritization of imaging cases for faster throughput
• Multi‑modal imaging support including CT, mammography and digital breast tomography
• Global scale deployment across hospitals and radiology networks in dozens of countries

Lunit is a South Korean‑based medical artificial intelligence company focused on advancing cancer diagnostics and therapy through deep‑learning‑based medical image analytics. The platform offers AI solutions that interpret radiologic studies such as chest X‑rays, mammograms and breast tomosynthesis, providing clinicians with probability estimates, visualization overlays and workflow integration to support faster and more accurate decision‑making. At its core the technology is developed on large curated datasets of de‑identified medical images and has been validated through peer‑reviewed research in major journals and clinical deployments worldwide.
Hospitals and radiology networks adopt Lunit’s AI suite to improve screening sensitivity, reduce missed findings and streamline workflows. For example the chest‑X‑ray solution can detect lung nodules and pneumothorax with high accuracy while the breast‑imaging tool supports earlier detection of breast cancer and can reduce workload by acting as a “second reader.” The company supports both cloud‑based and on‑site deployments and integrates with PACS/RIS systems for smooth clinical operation.
The value proposition lies in converting image data into actionable insights: Lunit’s AI highlights suspicious findings, quantifies lesion risk and surfaces metrics that enable radiologists and oncologists to make informed diagnoses and treatment‑planning decisions. While pricing is tailored for enterprise healthcare roles and the solution is not free, the investment is justified by workflow efficiency gains, improved diagnostic accuracy and potential to improve patient outcomes. As imaging volumes continue to increase and radiologist shortages persist globally, Lunit positions itself as a partner for radiology services, hospitals and screening programmes.

Alternative to  Lunit